Royce & Associates’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.47M | Sell |
256,269
-386,497
| -60% | -$6.74M | 0.05% | 484 |
|
|
2025
Q1 | $8.09M | Sell |
642,766
-286,847
| -31% | -$3.61M | 0.09% | 339 |
|
|
2024
Q4 | $9.81M | Buy |
929,613
+238,158
| +34% | +$2.51M | 0.09% | 327 |
|
|
2024
Q3 | $10M | Buy |
691,455
+45,755
| +7% | +$663K | 0.09% | 319 |
|
|
2024
Q2 | $5.49M | Buy |
645,700
+87,000
| +16% | +$740K | 0.05% | 455 |
|
|
2024
Q1 | $5.71M | Buy |
558,700
+85,000
| +18% | +$869K | 0.05% | 466 |
|
|
2023
Q4 | $2.6M | Buy |
473,700
+10,000
| +2% | +$54.8K | 0.02% | 613 |
|
|
2023
Q3 | $1.75M | Hold |
463,700
| – | – | 0.02% | 663 |
|
|
2023
Q2 | $3.11M | Buy |
463,700
+159,800
| +53% | +$1.07M | 0.03% | 596 |
|
|
2023
Q1 | $1.98M | Buy |
+303,900
| New | +$1.98M | 0.02% | 656 |
|